Neurofibromatosis Type 2 Until 2018,<unk>  was only indicated for patients with Neurofibromatosis Type 2 (NF2). NF2 is a genetic disorder that is characterised by the development of non-cancerous tumours along the nervous system. These vestibular schwannomas (also known as acoustic neuromas) often form on the<unk>  nerve, and surgical removal of these NF2 tumours can damage the<unk>  nerve and limiting the patient's<unk> lity to hear. NF2 generally presents in adolescence or young adulthood, so candidacy was previously limited to patients aged 15 years or older, with NF2 and bilateral non-functioning<unk>  nerves. Other Indications In Europe and other countries,<unk>  is CE-marked and approved for patients 12 months and older who cannot benefit from a cochlear implant due to non-functional<unk>  nerves. This includes both congenital and accrued etiologies, including: *<unk>  nerve aplasia *<unk>  nerve hypoplasia * Head trauma * Non-NF2 tumours * Severe cochlear ossification In the USA, a handful of medical centres, including New York University, are undergoing FDA approved feasibility studies in the pediatric population.
Auditory brainstem implant
Vibroacoustic therapy
Totally implantable cochlear implant
Audio therapy
Direct acoustic cochlear implant
Bone-anchored hearing aid
Cochlear implant
Middle ear implant